DAVID GOULD: Open Payments
NPI 1629068077 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,858 in 94 payments from 20 companies in 2025. Trend: 2023 $1,453 · 2024 $2,084 · 2025 $1,858
Food & beverage: $1,858
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $304 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $255 |
| Neurocrine BioSciences, Inc. | 8 | $177 |
| E.R. Squibb & Sons, L.L.C. | 9 | $177 |
| Otsuka America Pharmaceutical, Inc. | 11 | $160 |
| Janssen Pharmaceuticals, Inc | 5 | $145 |
| Axsome Therapeutics, Inc. | 4 | $95 |
| Almatica Pharma LLC | 3 | $58 |
| Collegium Pharmaceutical, Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $53 |
Products named: CAPLYTA, FANAPT, INGREZZA, COBENFY, REXULTI, Auvelity, SPRAVATO, HETLIOZ.
Industry payments across VA — which companies pay providers there.
